These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 29938471)
1. An Interleukin-6 Single Nucleotide Polymorphism and Susceptibility to Prostate Adenocarcinoma and Bone Metastasis in an Iranian Population. Dargahi Abbasabad G; Banan Khojasteh SM; Eskandari Naji H; Zamani MR; Hajipour H; Serati-Nouri H Asian Pac J Cancer Prev; 2018 Jun; 19(6):1717-1720. PubMed ID: 29938471 [TBL] [Abstract][Full Text] [Related]
2. The Role of Interleukin-6 Polymorphism (rs1800795) in Prostate Cancer Development and Progression. Jurečeková J; Drobková H; Šarlinová M; Babušíková E; Sivoňová MK; Matáková T; Kliment J; Halašová E Anticancer Res; 2018 Jun; 38(6):3663-3667. PubMed ID: 29848725 [TBL] [Abstract][Full Text] [Related]
4. IL-6 Genomic Variants and Risk of Prostate Cancer. Taheri M; Noroozi R; Rakhshan A; Ghanbari M; Omrani MD; Ghafouri-Fard S Urol J; 2019 Oct; 16(5):463-468. PubMed ID: 30345492 [TBL] [Abstract][Full Text] [Related]
5. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Wang L; Habuchi T; Mitsumori K; Li Z; Kamoto T; Kinoshita H; Tsuchiya N; Sato K; Ohyama C; Nakamura A; Ogawa O; Kato T Int J Cancer; 2003 Jan; 103(1):116-20. PubMed ID: 12455063 [TBL] [Abstract][Full Text] [Related]
6. Kallikarein-related peptidase 3 common genetic variant and the risk of prostate cancer. Motamedi RK; Sarhangi N; Afshari M; Sattari M; Jamaldini SH; Samzadeh M; Mohsen Ziaei SA; Pourmand GR; Hasanzad M J Cell Biochem; 2019 Sep; 120(9):14822-14830. PubMed ID: 31017705 [TBL] [Abstract][Full Text] [Related]
7. Interleukin (IL)-8 polymorphisms and risk of prostate disorders. Taheri M; Noroozi R; Dehghan A; Roozbahani GA; Omrani MD; Ghafouri-Fard S Gene; 2019 Apr; 692():22-25. PubMed ID: 30641210 [TBL] [Abstract][Full Text] [Related]
8. Role of interleukin-6 gene polymorphisms in the development of prostate cancer. Chen CH; Gong M; Yi QT; Guo JH Genet Mol Res; 2015 Oct; 14(4):13370-4. PubMed ID: 26535651 [TBL] [Abstract][Full Text] [Related]
9. Immunogenetics of prostate cancer and benign hyperplasia--the potential use of an HLA-G variant as a tag SNP for prostate cancer risk. Zambra FM; Biolchi V; de Cerqueira CC; Brum IS; Castelli EC; Chies JA HLA; 2016 Feb; 87(2):79-88. PubMed ID: 26889902 [TBL] [Abstract][Full Text] [Related]
10. Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men. Takahashi H; Lu W; Watanabe M; Katoh T; Furusato M; Tsukino H; Nakao H; Sudo A; Suzuki H; Akakura K; Ikemoto I; Asano K; Ito T; Wakui S; Muto T; Hano H Int J Cancer; 2003 Nov; 107(2):224-8. PubMed ID: 12949798 [TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Wang L; Habuchi T; Tsuchiya N; Mitsumori K; Ohyama C; Sato K; Kinoshita H; Kamoto T; Nakamura A; Ogawa O; Kato T Cancer Res; 2003 Aug; 63(15):4407-11. PubMed ID: 12907612 [TBL] [Abstract][Full Text] [Related]
13. Association of IL-1β and IL-10 Polymorphisms with Prostate Cancer Risk and Grade of Disease in Eastern Croatian Population. Horvat V; Mandić S; Marczi S; Mrčela M; Galić J Coll Antropol; 2015 Jun; 39(2):393-400. PubMed ID: 26753456 [TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia. Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073 [TBL] [Abstract][Full Text] [Related]
15. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer. Zambra FM; Biolchi V; Brum IS; Chies JA Hum Immunol; 2013 Aug; 74(8):1003-8. PubMed ID: 23632061 [TBL] [Abstract][Full Text] [Related]
16. SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients. Winchester D; Ricks-Santi L; Mason T; Abbas M; Copeland RL; Beyene D; Jingwi EY; Dunston GM; Kanaan YM Anticancer Res; 2015 Jul; 35(7):3811-9. PubMed ID: 26124326 [TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 promoter variants, prostate cancer risk, and survival. Tindall EA; Severi G; Hoang HN; Southey MC; English DR; Hopper JL; Giles GG; Hayes VM; Prostate; 2012 Dec; 72(16):1701-7. PubMed ID: 22782910 [TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 polymorphism and prostate cancer risk in population of Eastern Croatia. Mandić S; Sudarević B; Marczi S; Horvat V; Cosić I; Mihaljević S; Milicević N; Simunović D; Galić J Coll Antropol; 2013 Sep; 37(3):907-11. PubMed ID: 24308236 [TBL] [Abstract][Full Text] [Related]
19. Relationship between single nucleotide polymorphisms in -174G/C and -634C/G promoter region of interleukin-6 and prostate cancer. Bao S; Yang W; Zhou S; Ye Z J Huazhong Univ Sci Technolog Med Sci; 2008 Dec; 28(6):693-6. PubMed ID: 19107369 [TBL] [Abstract][Full Text] [Related]
20. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Jerónimo C; Varzim G; Henrique R; Oliveira J; Bento MJ; Silva C; Lopes C; Sidransky D Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):445-50. PubMed ID: 12010858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]